412269-00-2 Usage
Description
3-(3-Phenylsulfamoylphenyl)acrylic acid is a chemical compound with the molecular formula C17H15NO4S. It belongs to the class of organic compounds known as aryl-phenylacetylenes and is a derivative of acrylic acid. 3-(3-PhenylsulfaMoylphenyl)acrylic acid contains a sulfonyl group and a phenyl group, making it a member of the sulfonylbenzenes and phenyl sulfones classes. Its unique structure and properties suggest potential use as a pharmaceutical intermediate and may have applications in the development of new drugs or other organic compounds. However, further research is needed to fully understand its potential uses and properties.
Uses
Used in Pharmaceutical Industry:
3-(3-Phenylsulfamoylphenyl)acrylic acid is used as a pharmaceutical intermediate for the development of new drugs or other organic compounds. Its unique structure and properties make it a promising candidate for creating novel therapeutic agents.
Used in Organic Chemistry Research:
3-(3-Phenylsulfamoylphenyl)acrylic acid is used as a research compound in organic chemistry to explore its potential applications and properties. Further studies are required to understand its full potential and to develop new methods for its synthesis and utilization.
Check Digit Verification of cas no
The CAS Registry Mumber 412269-00-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,2,2,6 and 9 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 412269-00:
(8*4)+(7*1)+(6*2)+(5*2)+(4*6)+(3*9)+(2*0)+(1*0)=112
112 % 10 = 2
So 412269-00-2 is a valid CAS Registry Number.
412269-00-2Relevant articles and documents
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors
Zheng, Shilong,Guo, Shanchun,Zhong, Qiu,Zhang, Changde,Liu, Jiawang,Yang, Lin,Zhang, Qiang,Wang, Guangdi
, p. 149 - 154 (2018)
Despite promising therapeutic utilities for treatment of hematological malignancies, histone deacetylase inhibitor (HDACi) drugs have not proven as effective in the treatment of solid tumors. To expand the clinical indications of HDACi drugs, we developed novel boron-containing prodrugs of belinostat (2), one of which efficiently releases active 2 through a cascade of reactions in cell culture and demonstrates activities comparable to 2 against a panel of cancer cell lines. Importantly, prodrug 7 is more efficacious than belinostat in vivo, not only inhibiting the growth of tumor but also reducing tumor volumes in an MCF-7 xenograft tumor model owing to its superior biocompatibility, which suggests its clinical potential in the treatment of solid tumors.
COMPOUNDS AND METHODS FOR TREATING CANCER
-
, (2020/12/19)
Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.
